Hepatitis C virus quasispecies in chronically infected children subjected to interferon–ribavirin therapy

Accumulating evidence suggests that certain features of hepatitis C virus (HCV), especially its high genetic variability, might be responsible for the low efficiency of anti-HCV treatment. Here, we present a bioinformatic analysis of HCV-1a populations isolated from 23 children with chronic hepatitis C (CHC) subjected to interferon–ribavirin therapy. The structures of the viral quasispecies were established based on a 132-amino-acid sequence derived from E1/E2 protein, including hypervariable region 1 (HVR1). Two types of HCV populations were identified. The first type, found in non-responders, contained a small number of closely related variants. The second type, characteristic for sustained responders, was composed of a large number of distantly associated equal-rank variants. Comparison of 445 HVR1 sequences showed that a significant number of variants present in non-responding patients are closely related, suggesting that certain, still unidentified properties of the pathogen may be key factors determining the result of CHC treatment.

[1]  J. L. Sims.  Management of hepatitis. , 1969, Wisconsin medical journal.

[2]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[3]  Sims Jl.  Management of hepatitis. , 1969, Wisconsin medical journal.

[4]  H. Thomas,et al.  Changes in hypervariable region 1 of the envelope 2 glycoprotein of hepatitis C virus in children and adults with humoral immune defects , 2003, Journal of medical virology.

[5]  E. Domingo,et al.  Quasispecies dynamics and RNA virus extinction. , 2005, Virus research.

[6]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[7]  A. Alberti,et al.  Management of hepatitis C. , 2003, Journal of hepatology.

[8]  Angelo Balestrieri,et al.  Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Sergei L. Kosakovsky Pond,et al.  Datamonkey: rapid detection of selective pressure on individual sites of codon alignments , 2005, Bioinform..

[10]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[11]  Marek Figlerowicz,et al.  Genetic variability: The key problem in the prevention and therapy of RNA‐based virus infections , 2003, Medicinal research reviews.

[12]  P. Marcellin,et al.  Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose , 2002 .

[13]  N. Enomoto,et al.  Changes of HCV quasispecies during combination therapy with interferon and ribavirin. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[14]  P. Farci,et al.  Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Marcus Teo,et al.  Management of hepatitis C. , 2004, British medical bulletin.

[16]  M. Jonas.  Children with hepatitis C , 2002 .

[17]  J. Pawlotsky,et al.  Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): Influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C , 1998, Journal of medical virology.

[18]  Steven R. Martin,et al.  Differing Patterns of Liver Disease Progression and Hepatitis C Virus (HCV) Quasispecies Evolution in Children Vertically Coinfected with HCV and Human Immunodeficiency Virus Type 1 , 2004, Journal of Clinical Microbiology.

[19]  H. Toyoda,et al.  Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. , 1997, Journal of hepatology.

[20]  G. Deléage,et al.  Conservation of the Conformation and Positive Charges of Hepatitis C Virus E2 Envelope Glycoprotein Hypervariable Region 1 Points to a Role in Cell Attachment , 2001, Journal of Virology.

[21]  P. Ferenci.  Predictors of response to therapy for chronic hepatitis C. , 2004, Seminars in liver disease.

[22]  S. Elena,et al.  Basic concepts in RNA virus evolution , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  F. Puig-Basagoiti,et al.  Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. , 2005, The Journal of general virology.

[24]  I. Moreau,et al.  Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a , 2008, Virology Journal.

[25]  M. Mizokami,et al.  Determination of HCV quasispecies by cloning and sequencing. , 1999, Methods in molecular medicine.

[26]  Joel Dudley,et al.  MEGA: A biologist-centric software for evolutionary analysis of DNA and protein sequences , 2008, Briefings Bioinform..

[27]  P. Simmonds,et al.  Genetic diversity and evolution of hepatitis C virus--15 years on. , 2004, The Journal of general virology.

[28]  A. Alberti,et al.  Evolution of Hepatitis C Virus Quasispecies in Children with Chronic Hepatitis C , 2006, Infection.

[29]  M. Figlerowicz,et al.  Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C , 2004, European Journal of Pediatrics.

[30]  C. Guzmán,et al.  Evolution of hepatitis C virus hypervariable region 1 in immunocompetent children born to HCV‐infected mothers , 2009, Journal of viral hepatitis.

[31]  Steven R. Martin,et al.  HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[32]  Karina Yusim,et al.  The Los Alamos hepatitis C sequence database , 2005, Bioinform..

[33]  M. Nei,et al.  MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. , 2007, Molecular biology and evolution.